Rein Therapeutics (RNTX) news
Recent news
Pvt placement to provide North Immunology ~$180M gross proceeds
North Immunology has announced the completion of a private placement financing that is expected to generate approximately $180 million in gross proceeds. This capital infusion will support the company’s ongoing research and development initiatives, as well as its broader operational needs. The move…
AInvest Wire · Sep 17, 2026Rein Therapeutics Inc gets FDA fast track designation
AInvest Wire · Aug 20, 2026Rein Therapeutics Inc. <RNTX.O>: H.C. Wainwright cuts target price to $8 from $10
H.C. Wainwright has revised its price target for Rein Therapeutics Inc. (RNTX.O), reducing it to $8 from $10, while maintaining a Buy rating. The adjustment reflects the firm’s reassessment of the company’s near-term financial trajectory and market dynamics. Rein Therapeutics, a biopharmaceutical…
AInvest Wire · Jun 1, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.